Aberrant vascular architecture in tumors and its importance in drug-based therapies.

The vasculature is not simply a collection of hollow tubes through which blood flows - it is an organ in its own right, consisting of several cell types organized in a specific manner, and it mediates many unique biological and physiological functions such as selective filtration and angiogenesis. In tumors, blood vessels have structural and functional abnormalities that, to date, have generally hindered conventional therapies: the malformed networks make it difficult to deliver drugs uniformly to all cancer cells. Furthermore, flow in these vessels is chaotic, with intermittent stagnation followed by high-flow or even flow reversal in isolated segments. Cancer cells in stagnated or low-flow regions will receive suboptimal drug levels during chemotherapy. However, as more is learned about the formation of tumor vasculature and how it differs from that in normal tissue, more effective and directed therapies to fight cancer might be developed.

[1]  H. Dvorak Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. , 1986, The New England journal of medicine.

[2]  Paul S. Meltzer,et al.  Expression and functional significance of VE-cadherin in aggressive human melanoma cells: Role in vasculogenic mimicry , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[3]  R K Jain,et al.  Openings between defective endothelial cells explain tumor vessel leakiness. , 2000, The American journal of pathology.

[4]  H. Dvorak,et al.  The vesiculo‐vacuolar organelle (VVO): a distinct endothelial cell structure that provides a transcellular pathway for macromolecular extravasation , 1996, Journal of leukocyte biology.

[5]  J. Isner,et al.  Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. , 1999, Circulation research.

[6]  Rakesh K Jain,et al.  Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. , 2002, The American journal of pathology.

[7]  E. Ruoslahti,et al.  Fibronectin and its integrin receptors in cancer. , 1999, Advances in cancer research.

[8]  R K Jain,et al.  Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. , 1995, Cancer research.

[9]  G. Palade,et al.  Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor. , 1995, Journal of cell science.

[10]  R. Hesketh,et al.  Combretastatin-A4 disrupts neovascular development in non-neoplastic tissue , 2001, British Journal of Cancer.

[11]  W. Westlin Integrins as targets of angiogenesis inhibition. , 2001, Cancer journal.

[12]  R K Jain,et al.  Determinants of tumor blood flow: a review. , 1988, Cancer research.

[13]  Rakesh K. Jain,et al.  Transport of molecules across tumor vasculature , 2004, Cancer and Metastasis Reviews.

[14]  R K Jain,et al.  Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[15]  R K Jain,et al.  Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: implications for therapy. , 1990, Cancer research.

[16]  Y. Sasaki,et al.  Cyclooxygenase inhibitors suppress angiogenesis and reduce tumor growth in vivo. , 1999, Laboratory investigation; a journal of technical methods and pathology.

[17]  Grietje Molema,et al.  Tumor Infarction in Mice by Antibody-Directed Targeting of Tissue Factor to Tumor Vasculature , 1997, Science.

[18]  S. Ran,et al.  Tumor infarction by targeting tissue factor to tumor vasculature. , 2000, Cancer journal.

[19]  N. Fausto Vasculogenic mimicry in tumors. Fact or artifact? , 2000, The American journal of pathology.

[20]  A. Foss,et al.  Endothelial Cells of Tumor Vessels: Abnormal but not Absent , 2004, Cancer and Metastasis Reviews.

[21]  Chemoprevention of intestinal polyposis in the APCΔ716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor , 2000 .

[22]  R Folberg,et al.  Vasculogenic mimicry and tumor angiogenesis. , 2000, The American journal of pathology.

[23]  R. Jain The next frontier of molecular medicine: Delivery of therapeutics , 1998, Nature Medicine.

[24]  C. Betsholtz,et al.  Analysis of Mural Cell Recruitment to Tumor Vessels , 2002, Circulation.

[25]  P. Friedl,et al.  The biology of cell locomotion within three-dimensional extracellular matrix , 2000, Cellular and Molecular Life Sciences CMLS.

[26]  R. Jain,et al.  Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[27]  Michael D Feldman,et al.  Tumor vessel development and maturation impose limits on the effectiveness of anti-vascular therapy. , 2003, The American journal of pathology.

[28]  D. Ingber Extracellular matrix as a solid-state regulator in angiogenesis: identification of new targets for anti-cancer therapy. , 1992, Seminars in cancer biology.

[29]  A. Levine,et al.  Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo. , 2000, The Journal of urology.

[30]  Philippe Shubik,et al.  Vascularization of tumors: A review , 2004, Journal of Cancer Research and Clinical Oncology.

[31]  D. Chaplin,et al.  The development of combretastatin A4 phosphate as a vascular targeting agent. , 2002, International journal of radiation oncology, biology, physics.

[32]  Rakesh K. Jain,et al.  Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy , 2001, Nature Medicine.

[33]  R. Xavier,et al.  Tumor Induction of VEGF Promoter Activity in Stromal Cells , 1998, Cell.

[34]  R K Jain,et al.  Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[35]  R. Jain,et al.  Intussusceptive microvascular growth in a human colon adenocarcinoma xenograft: a novel mechanism of tumor angiogenesis. , 1996, Microvascular research.

[36]  P. Shubik,et al.  The growth of the blood supply to melanoma transplants in the hamster cheek pouch. , 1966, Laboratory investigation; a journal of technical methods and pathology.

[37]  D. Cheresh,et al.  Adhesion events in angiogenesis. , 2001, Current opinion in cell biology.

[38]  J. Tarbell,et al.  Kinetics of placenta growth factor/vascular endothelial growth factor synergy in endothelial hydraulic conductivity and proliferation. , 2001, Microvascular research.

[39]  M. Barcos,et al.  Induction of lasting complete regression of preformed distinct solid tumors by targeting the tumor vasculature using two new anti-endoglin monoclonal antibodies. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[40]  T W Gardner,et al.  Effect of vascular endothelial growth factor on cultured endothelial cell monolayer transport properties. , 2000, Microvascular research.

[41]  Dwayne G Stupack,et al.  ECM Remodeling Regulates Angiogenesis: Endothelial Integrins Look for New Ligands , 2002, Science's STKE.

[42]  R. Jain,et al.  During angiogenesis, vascular endothelial growth factor regulate natural killer cell adhesion to tumor endothelium , 1996, Nature Medicine.

[43]  B. Neustadt,et al.  Targeting integrins alpha v beta 3 and alpha v beta 5 for blocking tumor-induced angiogenesis. , 2000, Advances in experimental medicine and biology.

[44]  Rakesh K Jain,et al.  Lymphatic Metastasis in the Absence of Functional Intratumor Lymphatics , 2002, Science.

[45]  D. Cheresh,et al.  The role of alphav integrins during angiogenesis: insights into potential mechanisms of action and clinical development. , 1999, The Journal of clinical investigation.

[46]  R. Jain,et al.  Vascular Morphogenesis and Remodeling in a Human Tumor Xenograft: Blood Vessel Formation and Growth After Ovariectomy and Tumor Implantation , 2001, Circulation research.

[47]  J. Folkman,et al.  Clinical translation of angiogenesis inhibitors , 2002, Nature Reviews Cancer.

[48]  R K Jain,et al.  Effect of host microenvironment on the microcirculation of human colon adenocarcinoma. , 1997, The American journal of pathology.

[49]  A. Boulares,et al.  Induction of apoptosis in proliferating human endothelial cells by the tumor-specific antiangiogenesis agent combretastatin A-4. , 1998, Cancer research.

[50]  R. Jain,et al.  Vasculogenic mimicry: how convincing, how novel, and how significant? , 2000, The American journal of pathology.

[51]  P. Burri Intussusceptive microvascular growth, a new mechanism of capillary network formation. , 1992, EXS.

[52]  Lei Xu,et al.  Tumour biology: Herceptin acts as an anti-angiogenic cocktail , 2002, Nature.

[53]  H. Adlercreutz,et al.  Flavonoids, dietary-derived inhibitors of cell proliferation and in vitro angiogenesis. , 1997, Cancer research.

[54]  J. Folkman,et al.  Endostatin inhibits angiogenesis by stabilization of newly formed endothelial tubes , 2004, Angiogenesis.

[55]  P. Meltzer,et al.  Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. , 1999, The American journal of pathology.

[56]  P. Chiarugi,et al.  Endostatin: A Promising Drug for Antiangiogenic Therapy , 1999, The International journal of biological markers.

[57]  H. Augustin,et al.  Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. , 2000, Cancer research.

[58]  R. Jain,et al.  Microvascular architecture in a mammary carcinoma: branching patterns and vessel dimensions. , 1991, Cancer research.

[59]  K. Messmer,et al.  The fine structure of tumor blood vessels. I. Participation of non-endothelial cells in tumor angiogenesis. , 1985, International journal of microcirculation, clinical and experimental.

[60]  R. Jain,et al.  Vascular Morphogenesis and Remodeling in a Model of Tissue Repair: Blood Vessel Formation and Growth in the Ovarian Pedicle After Ovariectomy , 2001, Circulation research.

[61]  H. Dvorak Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[62]  R. Jain,et al.  Effect of local anti-VEGF antibody treatment on tumor microvessel permeability. , 1999, Microvascular research.

[63]  G. Winter,et al.  Single-chain antibody-based gene therapy: inhibition of tumor growth by in situ production of phage-derived human antibody fragments blocking functionally active sites of cell-associated matrices , 2002, Gene Therapy.

[64]  Koichi Hattori,et al.  Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? , 2002, Nature Reviews Cancer.

[65]  Napoleone Ferrara,et al.  Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. , 2002, Seminars in oncology.

[66]  D. Paper Natural products as angiogenesis inhibitors. , 1998, Planta medica.

[67]  R K Jain,et al.  Delivery of Molecular Medicine to Solid Tumors , 1996, Science.

[68]  R. Brekken,et al.  Vascular endothelial growth factor and vascular targeting of solid tumors. , 2001, Anticancer research.

[69]  P. D’Amore,et al.  Cellular interactions in vascular growth and differentiation. , 2001, International review of cytology.

[70]  G. Palade,et al.  Neovasculature induced by vascular endothelial growth factor is fenestrated. , 1997, Cancer research.

[71]  R Pasqualini,et al.  Molecular heterogeneity of the vascular endothelium revealed by in vivo phage display. , 1998, The Journal of clinical investigation.